The narrow field of cell therapies — currently focused on blood cancers — could soon be used to treat far more common tumors, autoimmune diseases, or even viruses, biotech executives told a crowd in Boston Thursday.

“People landed on the moon, right?” said Usman Azam, president and CEO of Tmunity, likening that achievement to two landmark FDA approvals for CAR-T drugs: Novartis’s leukemia drug Kymirah, and Gilead-owned Kite’s Yescarta, which is used to treat a form of non-Hodgkin lymphoma. “We now want to jump to Jupiter.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy